Alterations of 5-Hydroxymethylcytosine in Human Cancers
-
- Christopher Mariani
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5841 S. Maryland Ave., MC 2115, Chicago, IL 60637, USA
-
- Jozef Madzo
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5841 S. Maryland Ave., MC 2115, Chicago, IL 60637, USA
-
- Erika Moen
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5841 S. Maryland Ave., MC 2115, Chicago, IL 60637, USA
-
- Ali Yesilkanal
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5841 S. Maryland Ave., MC 2115, Chicago, IL 60637, USA
-
- Lucy Godley
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5841 S. Maryland Ave., MC 2115, Chicago, IL 60637, USA
Description
<jats:p>Prior to 2009, 5-methylcytosine (5-mC) was thought to be the only biologically significant cytosine modification in mammalian DNA. With the discovery of the TET enzymes, which convert 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC), however, intense interest has emerged in determining the biological function of 5-hmC. Here, we review the techniques used to study 5-hmC and evidence that alterations to 5-hmC physiology play a functional role in the molecular pathogenesis of human cancers.</jats:p>
Journal
-
- Cancers
-
Cancers 5 (3), 786-814, 2013-06-25
MDPI AG
- Tweet
Details 詳細情報について
-
- CRID
- 1361418520631112832
-
- ISSN
- 20726694
-
- Data Source
-
- Crossref